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Objectives The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding
in acute coronary syndromes (ACS).
Background Hemorrhagic complications have been strongly linked with subsequent mortality in patients with ACS.
Methods A total of 17,421 patients with ACS (including non–ST-segment elevation myocardial infarction [MI], ST-segment
elevation MI, and biomarker negative ACS) were studied in the ACUITY (Acute Catheterization and Urgent Inter-
vention Triage strategY) and the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in
Acute Myocardial Infarction) trials. An integer risk score for major bleeding within 30 days was developed from a
multivariable logistic regression model.
Results Non-coronary artery bypass graft surgery (CABG)-related major bleeding within 30 days occurred in 744 patients
(7.3%) and had 6 independent baseline predictors (female sex, advanced age, elevated serum creatinine and
white blood cell count, anemia, non–ST-segment elevation MI, or ST-segment elevation MI) and 1 treatment-
related variable (use of heparin  a glycoprotein IIb/IIIa inhibitor rather than bivalirudin alone) (model c-statistic
 0.74). The integer risk score differentiated patients with a 30-day rate of non–CABG-related major bleeding
ranging from 1% to over 40%. In a time-updated covariate-adjusted Cox proportional hazards regression model,
major bleeding was an independent predictor of a 3.2-fold increase in mortality. The link to mortality risk was
strongest for non–CABG-related Thrombolysis In Myocardial Infarction (TIMI)-defined major bleeding followed by
non-TIMI major bleeding with or without blood transfusions, whereas isolated large hematomas and CABG-
related bleeding were not significantly associated with subsequent mortality.
Conclusions Patients with ACS have marked variation in their risk of major bleeding. A simple risk score based on 6 baseline
measures plus anticoagulation regimen identifies patients at increased risk for non–CABG-related bleeding and
subsequent 1-year mortality, for whom appropriate treatment strategies can be implemented. (J Am Coll Car-
diol 2010;55:2556–66) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.076t
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ent risk factor for subsequent mortality in patients with
cute coronary syndromes (ACS) and in those undergoing
ercutaneous coronary intervention (PCI), representing a
azard equivalent to or greater than that for myocardial
nfarction (MI) (1–7). Major bleeding also considerably
rolongs the hospital stay and increases resource consump-
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June 8, 2010:2556–66 Risk Score to Predict Bleeding and Mortalityedications) is therefore an important objective in the
anagement of patients with ACS.
Current strategies to reduce hemorrhagic complications
nclude the use of newer antithrombotic medications with
educed potential for bleeding, avoidance of overdosing, and
dentifying patients at risk for major bleeding events (for
hom radial artery access or other approaches might be
ndicated) (9–13). Contemporary large-scale studies have
onsistently identified elderly patients, women, and patients
ith impaired renal function and/or baseline anemia to be at
ncreased risk for bleeding (5,6,12). The relative hazard of
hese factors and their interaction have been incompletely
haracterized, and large databases are required to identify
he independent correlates of bleeding. Identifying the
atient at risk for hemorrhagic complications is especially
mportant, given the introduction of newer, more potent
ntiplatelet and antithrombin agents, which might increase
leeding complications (14,15). The development of a
imple-to-use risk score for bleeding could standardize
uality of care and patient outcomes. Risk stratification
ould also be employed to compare outcomes across clinical
tudies and institutions. Therefore, we pooled the databases
rom the ACUITY (Acute Catheterization and Urgent
ntervention Triage strategY) and HORIZONS-AMI
Harmonizing Outcomes with RevasculariZatiON and
tents in Acute Myocardial Infarction) trials to develop and
est the performance of a practical risk score to predict the
isk and implications of major bleeding in ACS.
ethods
tudy design. The design and principal results of the
CUITY and HORIZONS-AMI trials have been pub-
ished (11,16–19). In brief, in the ACUITY trial, 13,819
atients with moderate- and high-risk ACS (unstable an-
ina or non–ST-segment elevation myocardial infarction
NSTEMI]) were randomly assigned in an open-label
ashion to 1 of 3 antithrombotic regimens before cardiac
atheterization: heparin (unfractionated or enoxaparin) plus
glycoprotein IIb/IIIa inhibitor (GPI), bivalirudin plus a
PI, or bivalirudin monotherapy, in which GPI admin-
stration was permitted only for bail-out indications
11,16,17). Patients assigned to a GPI arm were randomized
gain in a 2  2 factorial design to either upstream GPI
nitiation in all patients immediately after randomization or
o deferred GPI initiation for selective use in PCI patients
nly, starting in the catheterization laboratory. Either epti-
batide or tirofiban was permitted, per Food and Drug
dministration-approved labeling, for upstream use, and
ither eptifibatide or abciximab was permitted for deferred
elective use. The details of the dosing and timing of the
tudy medications have been previously described (11,16,17).
Coronary angiography was required within 72 h of
andomization with subsequent triage to PCI, coronary
rtery bypass graft surgery (CABG), or medical manage-
ent as per standard of care. Aspirin was administered wefore angiography. A loading
ose of 300 mg of clopidogrel
as required in all cases no later
han 2 h after PCI. Blood prod-
ct transfusions were performed
t the discretion of the treating
hysician for clinical indications.
In HORIZONS-AMI, 3,602
atients with ST-segment elevation
yocardial infarction (STEMI)
ho presented within 12 h after
ymptom onset in whom primary
CI was planned were randomly
ssigned in an open-label fashion
n a 1:1 ratio to treatment with
nfractionated heparin plus a GPI
r to bivalirudin monotherapy
18,19). Aspirin and clopidogrel
either 300 or 600 mg, at the
iscretion of the investigator) or
iclopidine (500 mg in the case of
llergy to clopidogrel) was admin-
stered before catheterization. The details of the study medi-
ation dosing and timing have been previously described
18,19). After patency was restored in the infarct-related vessel,
,006 eligible patients were randomly assigned again—in a 3:1
atio—to either TAXUS paclitaxel-eluting stents or uncoated
ut otherwise identical bare-metal stents (Boston Scientific,
atick, Massachusetts).
Major bleeding was defined in both trials as the compos-
te of intracranial or intraocular bleeding, access site hem-
rrhage requiring intervention, reduction in hemoglobin of
4 g/dl without or 3 g/dl with an overt bleeding source,
eoperation for bleeding, or blood product transfusion
11,16–19). For the purpose of this analysis, isolated hema-
omas have been excluded from the criteria for a major bleed
nd were analyzed separately. Bleeding was adjudicated as
hether related or not related to the performance of
ABG. All primary and secondary end points of the 2 trials
ncluding major bleeding were adjudicated by a blinded
linical Events Committee under the same supervision and
sing the same definitions (11,16–19). The ACUITY and
ORIZONS-AMI trials were conducted according to the
eclaration of Helsinki and were approved by the institu-
ional review board or ethics committee at each participating
enter, and all patients provided written informed consent.
tatistical analysis. The databases of the ACUITY and
ORIZONS-AMI trials were combined, from which the
nivariate associations of 20 baseline variables and random-
zed treatment with major bleeding within 30 days and
eath within 1 year were determined. A forward stepwise
ogistic regression model was used to identify the indepen-
ent predictors of non–CABG-related major bleeding
ithin 30 days; a p value 0.01 was the criterion for
nclusion in the final model. The logistic model predictor
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass graft surgery
CI  confidence interval
GPI  glycoprotein IIb/IIIa
inhibitor
HR  hazard ratio
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionas converted to a more user-friendly integer score, pre-
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Risk Score to Predict Bleeding and Mortality June 8, 2010:2556–66icting an individual’s probability of major bleeding within
0 days. With each quantitative factor grouped into conve-
ient categories (e.g., 10-year age-group), an individual’s
core increases by an integer amount for each level above the
owest category. Each integer amount is a rounding of the
xact figure obtained from the logistic model. We deter-
ined that a 0 score should mean that a person is at very low
isk (e.g., a man under age 50 years with the lowest-risk
ategory of each other predictor). Because the effect of
andomized treatment is assessed subsequently, the integer
isk score first assumes the patient received heparin plus a
PI. If instead they received bivalirudin monotherapy, one
an subtract 5 from the integer score.
The model’s goodness of fit was assessed by calculating
he risk score for every patient and categorizing these scores
nto 4 categories from low risk to very high risk. The actual
bserved percentage with a major bleed in each category was
ompared with the expected percentage, the latter being the
um of the individual predicted probabilities from the
ogistic model.
To investigate the impact of the occurrence of major
leeding and MI on the occurrence and timing of subse-
uent mortality, baseline and randomized treatment ad-
usted Cox models were fitted with each adverse event as a
ime-updated binary covariate (20). To estimate the time-
ependent risk on mortality of major bleeding and MI, the
ox models were extended to have different time-updated
inary covariates for different time intervals (i.e., days 0 to 1,
ays 2 to 7, days 8 to 30, and days 31 after the event).
urther models then introduced time-updated covariates for
different types of protocol-defined major bleed in increas-
ng order of severity: large hematoma only, other major
leed without blood transfusion, bleeding with blood trans-
usion, and Thrombolysis In Myocardial Infarction
TIMI)-defined major bleed. Each bleed was assigned to its
ost severe category.
All analyses were carried out with STATA version 10.1
StataCorp, College Station, Texas). All significance levels
re 2-sided. All statistical data analyses were performed at
n independent data coordinating center, separate from the
linical coordinating and data coordinating centers of these
trials.
esults
ncidence and predictors of non–CABG-related major
leeding. A non–CABG-related major bleed occurred
ithin 30 days of randomization in 520 (3.8%) of the
3,819 ACUITY patients and in 224 (6.2%) of the 3,602
ORIZONS-AMI patients. Within 1-year after random-
zation, death had occurred in 514 (3.7%) ACUITY pa-
ients and 146 (4.1%) HORIZONS-AMI patients. Table 1
isplays the univariate associations of 20 baseline character-
stics with 30-day major bleeding and with 1-year mortality
n the combined ACUITY and HORIZONS-AMI trials. (Multivariable analysis selected 6 baseline demographic
nd laboratory variables and 1 treatment-related variable
s independent predictors of non–CABG-related major
leeding within 30 days (Table 2): female sex, advanced
ge, elevated serum creatinine and white blood cell count,
nemia, presentation (STEMI and raised biomarkers
NSTEMI]), and randomized treatment (heparinGPI as
ompared with bivalirudin monotherapy [in ACUITY and
ORIZONS-AMI] and bivalirudin  GPI as compared
ith bivalirudin monotherapy [in ACUITY]) (model
-statistic  0.74). The integer risk score derived from this
odel appears in Figure 1. It consists of the summation of
integers (1 from each baseline variable), representing the
ndividual risk of bleeding if the patent received heparin 
GPI. If bivalirudin is administered instead, 5 points are
ubtracted from the integer score. Figure 2 shows the risk
istribution and the predicted probability of a major bleed in
ll 17,421 patients for each integer score, assuming they
ere taking heparin plus a GPI. From observation of
hese data, 4 categories of bleeding might arbitrarily be
efined: low, moderate, high, and very high, correspond-
ng to integer scores 10, 10 to 14, 15 to 19, and 20,
espectively (with 30-day non–CABG-related bleeding
ates of 1.9%, 3.3%, 6.9%, and 12.4%, respectively, in
atients treated with a heparin plus a GPI and 0.7%,
.0%, 3.7%, and 8.4%, respectively, in patients treated
ith bivalirudin monotherapy).
Table 3 shows the observed incidence of 30-day non–
ABG-related major bleeding by randomized treatment for
atients in these 4 risk categories as well as the expected
ncidence, on the basis of each individual patient’s predicted
isk calculated from the logistic model in Table 2. Close
greement between the observed and expected bleeding
ates were present. In all 4 risk categories the incidence of
ajor bleeding was higher in patients treated with heparin
lus a GPI compared with bivalirudin alone, although the
bsolute risk difference was greatest in those at very high risk
12.4% vs. 8.4%, representing 4 major bleeds prevented for
very 100 patients treated with bivalirudin monotherapy
ather than heparin plus a GPI).
on–CABG-related major bleeding and mortality risk.
able 4 presents the multivariable Cox model relating
eaths within 1 year (n  660 [3.8%] of 17,421 patients) in
he combined ACUITY/HORIZONS-AMI database to
ndependent baseline predictors. A total of 9 independent
redictors of 1-year mortality were identified, of which
dvanced age, elevated white blood cell count and serum
reatinine, diabetes, and reduced hemoglobin were the most
ighly significant. Randomized treatment assignment was
ot an independent predictor of mortality in this model.
Both the occurrence of non–CABG-related major bleed-
ng and MI within 30 days were independent predictors of
ubsequent mortality, when added to this multivariate
odel as time-updated covariates, with comparable hazard
atios (HRs) of 3.2 and 3.0, respectively, each p  0.001
Fig. 3). A difference in the temporal relationship between
t
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June 8, 2010:2556–66 Risk Score to Predict Bleeding and Mortalityhe impact of these variables on mortality was noted,
owever. After an MI the mortality risk declined over time,
uch that there is no evidence of excess mortality risk
eyond 30 days after the event, whereas after a non–
ABG-related major bleed the associated mortality increase
Baseline Characteristics by Non–CABG-RelatedProtocol-Defined Major Bleeding Within 30 DaysTable 1 B seline Characteristics by Non–CAProtocol-Defined Major Bleeding Wi
Total
Total 17,421
Study
ACUITY 13,819
HORIZONS-AMI 3,602
Presentation*
Biomarker-negative ACS 5,160
NSTEMI-raised biomarkers 7,552
STEMI 3,602
Treatment
UFH/Enox  GPI 6,405
Bivalirudin monotherapy 6,412
Bivalirudin  GPI 4,604
Age, yrs 62.1 11.7
Sex
Male 12,422
Female 4,999
Weight, kg 84.6 18.0
Ethnic group
Caucasian 15,605
Other 1,805
Diabetic status
Any 4,445
None 12,863
Noninsulin diabetes 3,093
Insulin-requiring diabetes 1,352
Current cigarette smoker 5,595
Hypertension 11,136
Previous MI 4,614
Previous PCI 5,706
Previous CABG 2,570
Serum creatinine, mg/dl
Median (IQR) 1.00 (0.82–1.1
n 2.5 mg/dl 108 (0.7%)
Creatinine clearance, ml/min
Median (IQR) 87 (66–112)
n 250 ml/min 41 (0.3%)
Hematocrit, % 41 5
Hemoglobin, g/dl 14.1 1.6
Anemia† 2,525
Platelet count, g/dl 240 69
White blood cell count, giga/l
Median (IQR) 8.5 (6.8–10.7
n 20 giga/l 136 (0.8%)
Values are n, n (%), or mean  SD unless otherwise indicated. *Bioma
HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and S
myocardial infarction (STEMI) presentation. †Men: hemoglobin 13 g
ACUITY  Acute Catheterization and Urgent Intervention Triage stra
MImyocardial infarction; PCI percutaneous coronary intervention;
IIb/IIIa inhibitor.emained significantly elevated even 30 days later. sTable 5 displays the hierarchical incidence of non–
ABG-related major bleeding within 30 days, ranked in
rder of severity (from greatest to least) as TIMI-defined
ajor bleed, non-TIMI major bleed with transfusion, major
leed without transfusion, and large hematoma only. Figure 4
Mortality Within 1 Yearelated
0 Days and Mortality Within 1 Year
Major Bleeding
Within 30 Days
Death
Within 1 Year
744 (4.3%) 660 (3.8%)
520 (3.8%) 514 (3.7%)
224 (6.2%) 146 (4.1%)
163 (3.2%) 128 (2.5%)
330 (4.4%) 341 (4.5%)
224 (6.2%) 146 (4.1%)
348 (5.4%) 258 (4.0%)
209 (3.3%) 229 (3.6%)
187 (4.1%) 173 (3.8%)
67.4 12.1 70.6 10.9
395 (3.2%) 461 (3.7%)
349 (7.0%) 199 (4.0%)
79.8 19.0 80.3 18.6
656 (4.2%) 595 (3.8%)
88 (4.9%) 65 (3.6%)
234 (5.3%) 251 (5.6%)
506 (3.9%) 404 (3.1%)
149 (4.8%) 148 (4.8%)
85 (6.3%) 103 (7.6%)
211 (3.8%) 171 (3.1%)
513 (4.6%) 480 (4.3%)
180 (3.9%) 210 (4.6%)
182 (3.2%) 201 (3.5%)
104 (4.0%) 137 (5.3%)
1.06 (0.87–1.30) 1.10 (0.90–1.39)
11 (1.6%) 12 (2.0%)
68 (49–92) 64 (47–83)
1 (0.1%) 1 (0.2%)
40 6 40 6
13.5 2.1 13.5 1.9
209 (8.3%) 178 (7.0%)
252 85 241 87
9.4 (7.5–12.1) 9.6 (7.6–12.7)
22 (3.1%) 19 (3.1%)
non–ST-segment elevation myocardial infarction (NSTEMI) patients;
Acute Myocardial Infarction) patients were all ST-segment elevation
men: hemoglobin 12 g/dl.
ABG  coronary artery bypass grafting; IQR  interquartile range;
nox GPI unfractionated heparin or enoxaparin plus a glycoproteinandBG-R
thin 3
4)
)
rkers in
tents in
/dl; wo
tegy; C
UFH/Ehows the relationship between the severity of non–
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*
0.05, 0.01, 0.001, 0.0001, and 0.00001, respectively.
CI  confidence interval; other abbreviations as in Table 1.
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Risk Score to Predict Bleeding and Mortality June 8, 2010:2556–66ABG-related major bleeding and subsequent mortality.
on–CABG-related bleeding meeting the TIMI major
riteria was an independent predictor of subsequent mor-
ality with an HR of 4.45. Non–CABG-related major
leeding requiring a blood transfusion but otherwise not
eeting the TIMI major criteria had a 3-fold increased
azard of mortality, whereas non-TIMI major bleeding not
equiring transfusion doubled the risk of subsequent mor-
ality. In contrast, development of a hematoma 5 cm
ithout more severe bleeding indexes was not a statistically
ignificant predictor of subsequent mortality.
ABG-related major bleeding. Among 1,600 patients
ho underwent a planned CABG within 30 days (1,539 and
1 patients in ACUITY and HORIZONS-AMI trials,
espectively), 857 (53.6%) experienced a CABG-related
ajor bleed (822 [53.4%] and 35 [57.4%] patients in the
CUITY and HORIZONS-AMI trials, respectively). In a
ime-updated baseline covariate-adjusted Cox model for mor-
ality, CABG-related major bleeding was not a significant
redictor of subsequent mortality in these patients (HR: 1.21,
5% confidence interval [CI]: 0.81 to 1.80, p  0.34).
iscussion
he main results of the present analysis based on the
ombined databases from 2 of the largest contemporary
eding
ry Syndrome
ount 11 giga/l, not anemic, and non–ST-segment elevation myocardial infarction
tal score, signifying a 9.6% chance of a non–coronary artery bypass graft
er than heparin plus glycoprotein IIb/IIIa inhibitor (GPI), the total score shouldFigure 1 Integer-Based Risk Score for Non–CABG-Related Major Ble
Within 30 Days of Patient Presentation With Acute Corona
Example: For a patient who is female, 72 years of age, creatinine 1.3 mg/dl, white cell c
(NSTEMI) without raised biomarkers, her risk score is: 8  9  3  2  0  0  22 to
(CABG)-related major bleed within 30 days (Fig. 2). *If patient is on bivalirudin alone rath
be reduced by 5. STEMI  ST-segment elevation myocardial infarction.ndependent Predictors ofon–CABG-Related Major Bleeding Within0 Days, With Multiple Logistic Regression
Table 2
Ind pendent Predi tors of
Non–CABG-Related Major Bleeding Within
30 Days, With Multiple Logistic Regression
Risk Factor
Odds
Ratio 95% CI Coefficient* z Value†
Sex
Male 1.00 — —
Female 2.32 1.98–2.72 0.84 10.36
Age, per 5 yrs 1.17 1.13–1.21 0.157 8.79
Serum creatinine, per 0.1 mg/dl 1.09 1.07–1.12 0.088 7.91
White blood cell count, giga/l 1.10 1.07–1.12 0.094 7.83
Anemia
No 1.00 — —
Yes 1.98 1.65–2.37 0.68 7.47
Presentation
Biomarker-negative ACS 1.00 — —
NSTEMI-raised biomarkers 1.26 1.04–1.54 0.23 2.30
STEMI 1.92 1.52–2.44 0.65 5.38
Randomized treatment
UFH/Enox  GPI 1.00 — —
Bivalirudin monotherapy 0.56 0.47–0.67 0.58 6.38
Bivalirudin  GPI 0.89 0.73–1.08 0.12 1.21
Intercept7.46; †Absolute value of z1.96, 2.58, 3.29, 3.89, and 4.42 corresponds to p value
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June 8, 2010:2556–66 Risk Score to Predict Bleeding and Mortalityandomized trials of patients with NSTEMI and STEMI
ndergoing an invasive management strategy are as follows:
) the risk of experiencing a non–CABG-related major
leed within 30 days of presentation varies greatly, depend-
ng to a large extent on baseline clinical characteristics,
aboratory results, and choice of anticoagulation regimen;
) a simple integer-based scoring system incorporating 7
ariables demonstrated good performance in identifying
atients with different risks for major bleeding; 3) the use of
ivalirudin as compared with heparin plus a GPI was
eneficial among patients with any degree of risk for
on–CABG-related major bleeding; 4) after accounting for
aseline predictors and therapies, both non–CABG-related
ajor bleeding and MI have a significant impact on
ubsequent mortality within 1-year; and 5) isolated large
ematoma was not a significant independent predictor of
ortality, whereas more severe forms of non–CABG-
elated major bleeding with or without blood transfusion
Figure 2 Distribution of the Integer Risk Score and Consequen
Assuming treatment with heparin  glycoprotein IIb/IIIa inhibitor. For patients trea
5 points should be subtracted from the score. CABG  coronary artery bypass gra
ncidence of Non–CABG-Related Major Bleeding Within 30 Days AcTable 3 Incidence of Non–CABG-Related Major Bleeding Within
Risk Category Integer Score
Heparin 
n Observed
Low 10 1,969 38 (1.9%)
Moderate 10–14 1,795 60 (3.3%)
High 15–19 1,406 97 (6.9%)
Very high 20 1,235 153 (12.4%)
Total 6,405 348 (5.4%)bbreviations as in Table 1.ignificantly predicted an increase in subsequent mortality.
ABG-related major bleeding, however, was not a signif-
cant predictor of subsequent death.
As more potent antithrombotic and antiplatelet agents
re being introduced to further reduce the incidence of
schemic events in patients with ACS, safety issues—
rincipally hemorrhagic complications—are emerging as a
ajor focus of attention (14,15). Understanding the predic-
ive factors for bleeding is especially important in light of
he multiple studies that have firmly established the strong
inkage between hemorrhagic complications of drugs and
rocedures and subsequent mortality in patients with ACS
nd in those treated with PCI (1–7). The present study
onfirms and extends these observations. In a time-updated,
ovariate-adjusted multivariable model, non–CABG-related
ajor bleeding was an independent predictor of subsequent
ortality, with an HR of 3.2 (95% CI: 2.6 to 3.9), comparable
n prognostic impact to MI after treatment.
bability of a Major Non–CABG-Related Bleed Within 30 Days
th bivalirudin monotherapy,
ng to Risk Score Category (%)ays According to Risk Score Category (%)
Bivalirudin Alone
Expected n Observed Expected
38.2 (1.9%) 1,876 14 (0.7%) 20.3 (1.1%)
65.3 (3.6%) 1,907 38 (2.0%) 39.0 (2.0%)
84.1 (6.0%) 1,362 51 (3.7%) 47.2 (3.5%)
160.4 (13.0%) 1,267 106 (8.4%) 102.5 (8.1%)
6,412 209 (3.3%)t Pro
ted wi
fting.cordi30 D
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Risk Score to Predict Bleeding and Mortality June 8, 2010:2556–66The present study has documented an enormous variation
n the likelihood for individual patients to develop a
on–CABG-related major bleed within 30 days of presen-
ation with ACS, ranging from 1% to over 40%, depending
n the patient’s risk profile. Non–CABG-related major
leeding was independently predicted by 6 baseline clinical
nd laboratory-based variables (female sex, advanced age,
ncreased serum creatinine and white blood cell count,
nemia, and admission for STEMI or NSTEMI). Several
f these factors have been previously described (5,6,21–24).
he finding of a higher white blood count predicting major
leeding, perhaps reflecting the influence of systemic in-
ammation, is novel and deserves future investigation. Of
ote, the rates of non–CABG-related major bleeding were
igher in patients enrolled with STEMI than with
STEMI (6.2% vs. 3.8%, respectively), although among
he latter major bleeding was increased in those with raised
iomarkers at baseline. The increased rate of bleeding in
atients with STEMI compared with NSTEMI might
eflect the urgency of care provided, more frequent use of
enous sheaths, unadjusted patient comorbidities, and the
ore frequent use of a 600-mg loading dose of clopidogrel
25–28). Furthermore, the GPI regimens used were some-
hat different in STEMI and NSTEMI in these studies. In
ndependent Predictors of 1-Year Mortalityrom Multivariable Cox RegressionTable 4 Ind pendent Predict rs of 1-Year MortalityFrom Multivariable Cox Regression
Risk Factor
Hazard
Ratio 95% CI Coefficient z Value*
Age, per 5 yrs 1.43 1.37–1.49 0.359 16.45
White blood cell count, giga/l 1.14 1.12–1.17 0.135 11.99
Serum creatinine, per 0.1 mg/dl 1.07 1.05–1.09 0.067 6.04
Diabetic status
No diabetes 1.00 — —
Noninsulin dependent 1.36 1.13–1.65 0.31 3.18
Insulin-dependent 1.92 1.53–2.41 0.65 5.61
Hemoglobin, g/dl 0.87 0.83–0.92 0.134 5.19
Presentation
Normal biomarkers 1.00 — —
Raised biomarkers 1.53 1.24–1.88 0.42 3.99
STEMI 1.39 1.07–1.82 0.33 2.43
Current smoker
No 1.00 — —
Yes 1.48 1.22–1.80 0.39 3.90
Sex
Male 1.00 — —
Female 0.76 0.63–0.91 0.27 2.93
Previous MI
No 1.00 — —
Yes 1.27 1.07–1.51 0.24 2.70
Randomized treatment
UFH/Enox  GPI 1.00 — —
Bivalirudin monotherapy 0.89 0.74–1.06 0.12 1.34
Bivalirudin  GPI 0.97 0.79–1.18 0.04 0.34
Absolute value of z1.96, 2.58, 3.29, 3.89, and 4.42 corresponds to p value0.05, 0.01, 0.001,
.0001, and 0.00001, respectively.
Abbreviations as in Tables 1 and 2.STEMI patients, approximately 60% of patients received Aptifibatide, followed by tirofiban (19%) and abciximab
17%), whereas STEMI patients received primarily abcix-
mab (52%) or eptifibatide (46%) but rarely tirofiban (0.2%).
n the Blue Cross Blue Shield of Michigan Cardiovascular
onsortium regional registry of contemporary PCI among
,541 patients undergoing primary PCI, gastrointestinal
leeding was more common in patients treated with abcix-
mab compared with eptifibatide, although the blood trans-
usion rate was comparable (29). In the randomized,
ouble-blind TARGET (Do Tirofiban and ReoPro Give
imilar Efficacy Trial), assignment to abciximab versus
irofiban resulted in similar rates of TIMI major bleeding
ut higher rates of TIMI minor bleeding with abciximab
30). Abciximab might also be associated with rates of
hrombocytopenia higher than other GPIs (31,32).
The frequency of major bleeding rose steadily with an
ncreasing risk score in patients treated with heparin plus a
PI or with bivalirudin monotherapy. However, use of
ivalirudin monotherapy rather than heparin plus a GPI
esulted in a significant reduction in non–CABG-related
ajor bleeding in both trials (a 39% reduction in the pooled
atabase) as well as across the spectrum of patients with low,
oderate, high, and very high risk score for major bleeding
relative reductions 63%, 39%, 46%, and 32%, respectively,
epresenting absolute reductions 1.2%, 1.3%, 3.2%, and
.0%, respectively). The choice of anticoagulant regimen
ith low bleeding potential is thus an important option to
ncrease the safety margin when managing patients with
CS. Several scoring systems have been developed to
redict major bleeding in patients treated with PCI. In
atients undergoing elective PCI in the STEEPLE (Safety
nd Efficacy of Enoxaparin in PCI Patients, an Interna-
ional Randomized Evaluation) trial, there were only 3
redictors of major bleeding, including female sex, the use
f unfractionated heparin versus enoxaparin, and the use of
PI versus no GPI (33). From the REPLACE (Random-
zed Evaluation in Percutaneous Coronary Intervention
inking Angiomax to Reduced Clinical Events)-1 and -2
andomized trials of patients undergoing PCI with princi-
ally stable ischemic heart disease, independent predictors
f major bleeding included age 73 years, female sex,
hronic renal insufficiency, baseline anemia, systolic blood
ressure 150 mm Hg, weight 70 kg, administration of
ow molecular weight heparin within 48 h before procedure,
se of intra-aortic balloon pump, and administration of GPI
34). In the OASIS-5 (Organization to Assess Strategies in
schemic Syndromes-5) trial of patients with ACS without
T-segment elevation, the GRACE (Global Registry of
cute Coronary Events) risk score (which is known to
redict in-hospital and 6-month mortality in patients with
CS) also had a modest ability to predict major bleeding
c-statistic 0.63) (28,35). Among community-treated
STEMI patients enrolled in the CRUSADE (Can Rapid
isk stratification of Unstable angina patients Suppress
Dverse outcomes with Early implementation of the
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June 8, 2010:2556–66 Risk Score to Predict Bleeding and MortalityCC/AHA guidelines) Quality Improvement Initiative,
he factors independently associated with in-hospital
ajor bleeding included baseline hematocrit, estimated
reatinine clearance, baseline heart rate, baseline systolic
lood pressure, female sex, signs of congestive heart failure
n presentation, prior vascular disease, and diabetes mellitus
c-statistic 0.71) (36). The c-statistic from the ACUITY/
ORIZONS-AMI model (0.74) is slightly higher than
hese previous models, suggesting better discrimination.
Of note, whereas both non–CABG-related bleeding and
I were independent predictors of mortality in our analysis,
he timing of the maximal impact of these adverse events
as different. This was previously reported by our group in
he population with NSTEMI (37) and now might be
xtended to the patients with STEMI. Specifically, the
Figure 3 Independent Hazard of the Occurrence of Major Non–C
and of MI Within 30 Days on Subsequent Mortality W
Adjusted for baseline predictors. Note: 98 patients had both a major bleed and a
For such patients, the models in Figure 3 have time-updated covariates for both e
ierarchical Incidence ofon–CABG-Related Major Bleeding Within 30 DaysTable 5 Hierarchical Incidence ofNon–CABG-Related Major Bleeding Within 30 Days
ACUITY
(n  13,819)
HORIZONS
(n  3,602)
Total
(n  17,421)
TIMI-defined major bleed 204 (1.5%) 84 (2.3%) 288 (1.7%)
Non-TIMI major bleed with
blood transfusion
190 (1.4%) 42 (1.2%) 232 (1.3%)
Non-TIMI major bleed without
blood transfusion
172 (1.2%) 98 (2.7%) 270 (1.5%)
Large hematoma only* 124 (0.9%) 14 (0.4%) 138 (0.8%)
Total 690 (5.0%) 238 (6.6%) 928 (5.3%)
ach patient is represented only once according to their most severe bleed. In the ACUITY trial, 46
hrombolysis In Myocardial Infarction (TIMI) bleeds were not included under the definition for majorr
leed. *Hematomas are not included in earlier analysis of major bleeds.
Abbreviations as in Table 1.azard of dying after an MI was sharply elevated within the
rst 24 h after the event, with a steep decline in prognostic
mpact beyond the first day, such that no significant increase
n the risk of death after the 30th day was present. In
ontrast, the impact of major bleeding on subsequent
ortality was significant both within and after 30 days. The
ossible mechanisms as to how bleeding might affect mor-
ality include hypovolemia and platelet activation that might
rovoke or exacerbate ischemia and arrhythmias, premature
iscontinuation of drugs known to improve outcomes after
CS, and the detrimental effects of blood product transfu-
ions (38–42). A potentially important finding from the
resent analysis is that the prognostic impact of bleeding
as found to directly correlate with the severity of the
leeding event, with all classes of non–CABG-related
leeding except isolated large (5 cm) hematomas having a
tatistically significant impact on 1-year mortality. In con-
rast, a femoral hematoma 4 cm in diameter was an
ndependent predictor of 30-day mortality from a study of
7,901 consecutive patients undergoing PCI from the Mayo
linic (43). However, in this study the hematoma had to be
ccompanied by a blood transfusion, surgery, or prolonged
ospital stay. The present study is, to our knowledge, the
rst to examine the impact of isolated hematomas and
ound that this adverse event, although uncomfortable and
isruptive to the patient’s recovery, does not significantly
ffect mortality and thus, in the absence of corrective
ntervention or transfusion, should not be included in future
-Related Bleed
1 Year
rdial infarction (MI) within 30 days, of whom 24 died within 1 year.
CABG  coronary artery bypass grafting; CI  confidence interval.ABG
ithin
myoca
vents.isk scores to predict mortality.
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Risk Score to Predict Bleeding and Mortality June 8, 2010:2556–66Finally, a novel finding from the present analysis is that
ABG-related major bleeding, which occurred in 54% of
atients undergoing planned CABG, did not significantly
redict subsequent mortality, with an HR of 1.21 (95% CI:
.81 to 1.80). This is potentially important, because medi-
ations that might decrease PCI-related ischemic compli-
ations but increase surgical bleeding (e.g., thienopyridines)
re often withheld from patients with ACS until angiogra-
hy confirms a likely nonsurgical management strategy.
oreover, 2 studies have now shown that thienopyridine
gents when administered before CABG in patients with
CS might decrease peri-surgical MI rates (44,45). This
act, coupled with the lack of effect of CABG-related
leeding on mortality after surgery in patients with ACS,
uggests that thienopyridine agents should be administered
s early as possible before cardiac catheterization (i.e., in the
mbulance or emergency room), so they might reach their
aximal effect in patients undergoing PCI, which repre-
ents the majority of the patients with both NSTEMI and
TEMI. Nonetheless, the relationship between the severity
f CABG-related bleeding and nonfatal clinical outcomes
hould be further assessed in future studies.
tudy limitations. Although the data were collected pro-
pectively, this was a post hoc analysis. Not all variables of
otential interest were available in both databases to allow
ncorporation into the risk model. Although the proposed
isk scoring system had adequate performance as assessed by
omparison of actual and predicted rates of major bleeding,
xternal validation in another dataset is desirable, especially
ecause the present model was created from randomized
linical trial data.
onclusions
hese limitations notwithstanding, we can conclude that for
ndividuals with ACS there is marked variation in the risk of
on–CABG-related major bleeding. A practical ACUITY/
ORIZONS-AMI scoring system with 6 readily available
aseline clinical and laboratory variables plus the anticoag-
lation regimen used provides a rapid and reliable tool to
Figure 4 Independent Hazard of the Occurrence of Different Typ
Major Bleed Within 30 Days on Subsequent Mortality
Adjusted for baseline predictors. CI  confidence interval; TIMI  Thrombolysis Inredict the rate of non–CABG-related major bleeding in Catients with ACS and its impact on subsequent mortality
ithin 1 year. Such knowledge will aid the accurate prog-
ostication of patients with ACS, facilitating appropriate
ersonalized decision-making for the patient at high risk of
leeding and mortality.
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